MustGrow annonce un placement sans intermédiaire sous le régime de la dispense pour financement de l'émetteur coté d'un montant maximal de 3 millions de dollars, une proposition de révision du prix des bons de souscription, et une offre d'actions aux porteurs de débentures aux fins du règlement de dettes
Saskatoon, Saskatchewan--(Newsfile Corp. - 12 août 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (la « Société » ou « MustGrow »), a le plaisir d'annoncer ce qui suit : i) un placement privé sans intermédiaire d'un maximum de 4 285 715 unités de la Société (chacune, une « unité ») au prix de 0,70 $ par unité pour un produit brut pouvant atteindre 3 000 000 $ (l
Agriculture, Biotechnology, Cannabis, Cannabis Breeder
2025-08-12 7:46 PM EDT | MustGrow Biologics Corp.
Medexus Announces Fiscal Q1 2026 Results, Including Positive Results from US Launch of GRAFAPEX (treosulfan) for Injection
Fiscal Q1 2026 net revenue of $24.6 million, net income of $0.5 million, operating income of $0.9 million, and Adjusted EBITDA* of $3.4 million $3.0 million of product-level net revenue from GRAFAPEX in fiscal Q1 2026, relative to $3.0 million of personnel and infrastructure investments, further supporting Medexus's confidence in the product's potential Management to host conferenc
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-08-12 5:30 PM EDT | Medexus Pharmaceuticals Inc.
Hemostemix Contracts Empire Market Ventures to Increase Market Awareness
Calgary, Alberta--(Newsfile Corp. - August 12, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it contracted Empire Market Ventures to provide an investor market awareness program. Empire Market Ventures (EMV) is a premier consulting firm and full-service advertising and investor awareness agency based in New York City. Specializing in strategic communications, digital media, and market intelligence, EMV delivers tailored solutions that enhance the visibility
Biotechnology, Pharmaceuticals, Health
2025-08-12 10:01 AM EDT | Hemostemix Inc.
BioMark Diagnostics Establishes African Market Presence Through Strategic Tunisia Healthcare Partnership
Vancouver, British Columbia--(Newsfile Corp. - August 12, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, announced today a strategic Expression of Interest (EOI) agreement with SAMA CONSULTING SARL ("SAMA CONSULTING") to explore the clinical application of BioMark's innovative liquid biopsy platform for lung cancer detection initially in Tunisia and later across the broader Nor
Technology, Biotechnology, Healthcare and Hospitals
2025-08-12 8:30 AM EDT | BioMark Diagnostics, Inc.
Izotropic Introduces New Corporate Website & Brand Identity
British Columbia and Sacramento, California--(Newsfile Corp. - August 12, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the launch of its new corporate website
2025-08-12 8:00 AM EDT | Izotropic Corporation
Quantum BioPharma Announces Update to Previously Announced Private Placement
Toronto, Ontario--(Newsfile Corp. - August 11, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announces that further to its press release dated June 27, 2025, the Company will be seeking shareholder approval of its non-brokered private placement of class A multiple voting shares ("MVS") for aggregate gross
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-08-11 6:32 PM EDT | Quantum BioPharma Ltd.
Marvel Biosciences Announces Grant of Deferred Share Units
Calgary, Alberta--(Newsfile Corp. - August 11, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announces the award of 142,987 deferred share units ("DSUs") to two of Marvel's directors, in lieu of cash payment for directors' fees. The DSUs will all vest on July 31, 2026. Vested DSUs shall be settled upon the directors' separation from service from the Company a
2025-08-11 6:05 PM EDT | Marvel Biosciences Corp.
PharmaTher Announces FDA Approval of Ketamine (KETARx(TM))
Toronto, Ontario--(Newsfile Corp. - August 11, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the pharmaceutical potential of ketamine, is pleased to announce that it received the U.S. Food and Drug Administration (FDA) approval for the Company's ketamine product, herein referred to as KETARx™, on August 8th, 2025, for its indicated uses in surgical pain manag
Biotechnology, Pharmaceuticals
2025-08-11 9:49 AM EDT | PharmaTher Holdings Ltd.
Entero Therapeutics, Inc. Announces $3.0 Million Private Placement Priced at the Market Under Nasdaq Rules
Boca Raton, Florida--(Newsfile Corp. - August 11, 2025) - Entero Therapeutics, Inc. (NASDAQ: ENTO) (the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of approximately $3 million of pre-funded and common warrants. The entire transaction has been priced at the market
Biotechnology, Pharmaceuticals
2025-08-11 7:30 AM EDT | Entero Therapeutics, Inc.
BioHarvest Sciences Reports Second Quarter 2025 Financial Results
Rehovot, Israel--(Newsfile Corp. - August 11, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the second quarter ended June 30, 2025. Second Quarter 2025 Highlights All figures stated in this news release are in U.S. dollars unless stat
Biotechnology, Pharmaceuticals, Health
2025-08-11 7:30 AM EDT | BioHarvest Sciences Inc.
Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference
Toronto, Ontario--(Newsfile Corp. - August 11, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that it will participate in a Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference in Boston, MA, on August 12, 2025, at 9:30 a.m. EDT. A live webcast o
Biotechnology, Cannabis, Health, Cannabis Manufacturer
2025-08-11 7:27 AM EDT | Cardiol Therapeutics Inc.
Scryb Inc. Provides Early Warning Update on Holdings In Cybeats Technologies Corp.
Toronto, Ontario--(Newsfile Corp. - August 8, 2025) - Scryb Inc. (CSE: SCYB) (OTC Pink: SCYRF) (FSE: EIY) ("Scryb") is issuing this release to report information concerning its holdings in Cybeats Technologies Corp. (the "Issuer"). This press release is issued pursuant to Multilateral Instrument 62-104 - Take-Over Bids and Issuer Bids ("NI 62-104") and National Instrument 62-103 - The Early Warning System and Related Take-Over Bid and Insider Reporting Issues
Biotechnology, Healthcare and Hospitals, Health
2025-08-08 8:25 PM EDT | Scryb Inc.
Kiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal Diseases
Encinitas, California--(Newsfile Corp. - August 8, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced second quarter 2025 financial results and provided an update on its pipeline of therapeutics for the treatment of retinal diseases. Key second quarter and 2025 year-to-date corporate highlights include: KIO-104 Initiated
Biotechnology, Pharmaceuticals
2025-08-08 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
Scryb Announces Effective Date of Proposed Share Consolidation
Toronto, Ontario--(Newsfile Corp. - August 7, 2025) - Scryb Inc. (CSE: SCYB) (OTC Pink: SCYRF) ("Scryb'' or the "Company"), is pleased to announce that further to its news release dated July 25, 2025, the Company will proceed with the consolidation of its issued and outstanding common shares (the "Common Shares") on the basis of one (1) new Common Share for every ten (10) old Common Shares (the "Consolidation"), effective as of August 13, 2025. The Consolidation
Biotechnology, Healthcare and Hospitals, Health
2025-08-07 10:20 PM EDT | Scryb Inc.
iSpecimen to Establish $200M Corporate Treasury Built Around Solana Cryptocurrency with BlockArrow
Woburn, Massachusetts--(Newsfile Corp. - August 7, 2025) - iSpecimen Inc. (NASDAQ: ISPC), a technology-enabled company modernizing the way human biospecimens are sourced for scientific research, today announced a major strategic initiative aimed at integrating digital assets into its business model. The company is looking to build an up to $200 million corporate treasury reserve based on the Solana blockchain ecosystem. iSpecimen has retained WestPark Capital to advise on the initiative
2025-08-07 4:05 PM EDT | iSpecimen Inc.
Maxwell Biosciences Announces Closing of $20M Financing Round
Austin, Texas--(Newsfile Corp. - August 7, 2025) - Maxwell Biosciences, a global health technology company pioneering a new category of immune-inspired small molecules called Claromers™, today announced the closing of its $20 million financing round. The funds will support Maxwell's upcoming FDA clinical trials and advance AI-driven R&D. The funds will also expand commercialization in multiple other industries in which nontoxic antiseptics are highly valued, such as cosmetics, clean
Biotechnology, Pharmaceuticals
2025-08-07 9:30 AM EDT | Maxwell Biosciences, Inc.
OS Therapies Announces Statistically Significant Positive Interim 2-Year Overall Survival Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
66.6% of OST-HER2 treated patients achieved 2-year overall survival compared with 40% in the historical control group (p = 0.0046) FDA issues Biologics Licensing Application (BLA) number for OST-HER2 in preparation for anticipated BLA filing for the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma following August 27, 2025 End of Phase 2 Meeting Company responds to FDA correspondences see
2025-08-07 9:00 AM EDT | OS Therapies
TempraMed Partners with the Diabetes Education & Camping Association of the USA (DECA), Supporting Safe Insulin Storage for Children at Diabetes Camps Across the United States
Sammamish, Washington--(Newsfile Corp. - August 7, 2025) - TempraMed Ltd. ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, is proud to announce a new partnership with the Diabetes Education & Camping Association (DECA) by providing VIVI Cap devices to diabetes camps across the United States. As part of this partnership, TempraMed is providing these critical temperature-sensitive s
Technology, Biotechnology, Pharmaceuticals, Health
2025-08-07 7:00 AM EDT | TempraMed Technologies Ltd
Kiora Pharmaceuticals to Showcase Its Retinal Disease Therapeutic Pipeline at The H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
Encinitas, California--(Newsfile Corp. - August 7, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that its President and CEO, Brian M. Strem, Ph.D., will showcase the Company's pipeline of therapies targeting inherited and inflammatory retinal diseases at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference. Presentation Details
Biotechnology, Pharmaceuticals
2025-08-07 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
OS Therapies Receives Positive Feedback from UK MHRA Scientific Advice Meeting and Submits Innovative Licensing and Access Pathway (ILAP) Request for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
New York, New York--(Newsfile Corp. - August 7, 2025) - OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that it held a successful Scientific Advice Meeting
2025-08-07 6:00 AM EDT | OS Therapies